
Tandem Diabetes Care wins FDA clearance for tubeless Mobi set worn up to 7 days
The new supplies work with existing pumps, with a U.S. launch planned for the first half of 2027 and access limited to pharmacy benefits.

The Financial Times identifies Amazon as the customer, while Fermi says a definitive long-term lease remains under negotiation.

The new supplies work with existing pumps, with a U.S. launch planned for the first half of 2027 and access limited to pharmacy benefits.

The applications follow a Phase 3 trial showing 27 per cent fewer painful crises versus placebo, with regulatory action expected in 2027.
A one-time gain is expected to exceed fourth-quarter operating expenses, while full-year guidance still calls for a loss.
Convertible-note principal stood at US$486.5 million, with about 16,116 bitcoin pledged as the company evaluates operating businesses.

The lender becomes its largest shareholder with 9.9 per cent, while the Okanjande stream expands to cover all future production.

Both headline growth rates compare with Q2, while Columbiana billing is expected to start in January 2027.

September liquidity of US$145.4 million is forecast to last into late 2028, beyond the expected ReVeRA-301 trial readout.

The existing 165 million USDT balance remains due in 2027, while eligible positive net derivatives value can count toward collateral requirements.
The Argentine acquisition brings a roughly US$13.8 million closure guarantee, assumed liabilities and a planned 2027 restart.
Omineca would retain a 50 per cent carried interest and receive half the recovered gold at a base cost of C$1,000 an ounce.
Uranium sales costs averaged US$87.22 per pound, while the producer awaits Texas approvals for extraction targets before year-end.
OPG is reassessing Darlington's first SMR budget and schedule, with its assessment due to be substantially complete by mid-2027.
The partners will combine CPUs, GPUs and adaptive computing, with more details due at Chicago's SC26 conference on Nov. 15 to 20.
True widths are estimated at 70 to 90 per cent of drilled lengths, with assays from 54 holes still pending.
International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The explorer will reassess working capital needs and financing alternatives after dropping its October offering.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Twelve participants stopped intravenous glucose, while final statistics are due in December and a US$100M offering is expected to close Nov. 16.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The Alberta proposal carried an estimated US$30M to US$35M cost, while token revaluation drove the quarterly profit.
The Grand Est site will recover cobalt, nickel and copper from black mass, but Veolia disclosed no investment cost or earnings forecast.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Prepayments will help fund U.S. enrichment capacity, with enough HALEU for up to five Aurora powerhouses over multiple years.

The proposed 1 GW facility accounts for most of the announced budget, but ReNew has disclosed neither financing terms nor a delivery date.

About 3,000 tonnes are planned for TotalEnergies' Leuna refinery in 2027 as the partners begin testing the integrated supply chain.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.

The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.

Operating cash flow reached US$9.5 million as expansion spending eased, but weaker Canadian wholesale pricing reduced cannabis profit.